The Life Sciences team represented Tranquis Therapeutics on its $30 million Series A financing. The financing was co-led by Remiges Ventures and SR One, and included participation from Vivo Capital, Hillsborough Venture, Correlation Ventures and other investors.
Tranquis Therapeutics is focused on discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on groundbreaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis’ novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company’s portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer’s Disease.
The Goodwin team was led by Sam Zucker and Deepa Rich with support by Shoaib Ghias.
For more details on the financing round, please read the press release and coverage in Endpoints and FierceBiotech.